Resources
Paper
Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotech Reports. 2017; 15:24-26.
Paper
Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotech Reports. 2017; 15:24-26.
Publication
BioWorld Today Ricin Toxin Program Review
In a recent article in BioWorld Today, the Soligenix ricin toxin vaccine program was reviewed, including comments from Dr. Oreola Donini, Chief Scientific Officer of Soligenix.
Presentation
Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease
Donini O. Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease – “Supercharging existing and new antibiotic therapies”. Presentation at the 2017 Superbugs & Superdrugs Meeting. March 20-21, 2017.
Presentation
Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease-Supercharging existing and new antibiotic therapies
Donini O. Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease – “Supercharging existing and new antibiotic therapies”. Presentation at the 2017 Superbugs & Superdrugs Meeting. March 20-21, 2017.
Paper
Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis S, Straube S, Donini O. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotech 2016; 239: 115-125.
Paper
Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis S, Straube S, Donini O. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotech 2016; 239: 115-125.
Publication
Journal of Biotechnology – Dusquetide: A Novel Innate Defense Regulator Demonstrating a Significant and Consistent Reduction in the Duration of Oral Mucositis in Preclinical Data and a Randomized, Placebo-Controlled Phase 2a Clinical Study
The publication of positive clinical results consistent with preclinical data
Poster
Orphan Disease, Biodefense and the Animal Rule: A Thermostabilized Ricin Toxin Vaccine
Donini O, Haulenbeek A, Arumugham R, Schaber C. Orphan Disease, Biodefense and the Animal Rule: A Thermostabilized Ricin Toxin Vaccine. Poster Presentated at the National Organization for Rare Diseases (NORD) Rare Diseases and Orphan Products Breakthrough Summit.